NCT03344016 Multicenter Pheochromocytoma and Paraganglioma Evaluation
| NCT ID | NCT03344016 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Felix Beuschlein |
| Condition | Pheochromocytoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,148 participants |
| Start Date | 2017-11-01 |
| Primary Completion | 2035-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,148 participants in total. It began in 2017-11-01 with a primary completion date of 2035-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes. International multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up). All patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.
Eligibility Criteria
Inclusion Criteria: male and female patients (≥ 5 years of age), who fulfill one or more of the following criteria: (i) Patients with a newly diagnosed PPGL. (ii) Patients with a previous history of PPGLs. (iii) Carrier of genetic mutations known to predispose for the development of PPGLs. All subjects must have read, understood and signed the informed consent form, before inclusion into the study protocol. Signed parental consent must be obtained for children with suspected PPGLs who are enrolled in the study. Exclusion Criteria: * Patients with impaired mental capacity that precludes informed consent. * Pregnancy does not constitute criteria for exclusion from the protocol. However, in pregnant women no Clonidine testing, no PET scanning, MIBG scanning or contrast CT will be performed. * Patients at risk from injury from the MRI magnet due to implantable metal or who suffer from anxiety in enclosed spaces are excluded from MRI.
Contact & Investigator
Felix Beuschlein, M.D.
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT03344016 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, studying Pheochromocytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03344016 currently recruiting?
Yes, NCT03344016 is actively recruiting participants. Contact the research team at felix.beuschlein@usz.ch for enrollment information.
Where is the NCT03344016 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT03344016 clinical trial?
NCT03344016 is sponsored by Felix Beuschlein. The principal investigator is Felix Beuschlein, M.D. at University of Zurich. The trial plans to enroll 1,148 participants.